Skip to main content
OpenTrials

Clinical trial condition

Male Urogenital Diseases

Explore clinical trials studying Male Urogenital Diseases. Study availability and eligibility vary by location and protocol.

20,869 public trials 3,484 recruiting studies
Refine in advanced search Browse all conditions

Male Urogenital Diseases trial results

Recruiting

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

NCT07227402

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Alaska Oncology and Hematology ( Site 0133) Anchorage, Alaska, United States
  • Providence Medical Foundation ( Site 0141) Fullerton, California, United States
  • Cedars-Sinai Medical Center ( Site 0112) Los Angeles, California, United States
  • New England Cancer Specialists ( Site 0132) Westbrook, Maine, United States
View all 127 locations
View Trial Details
Recruiting

Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease

NCT05732727

Conditions
Chronic Disease, Chronic Kidney Disease(CKD), Disease Attributes, +11 more
Locations
  • Department of Nephrology, University Hospital of Angers Angers, France
  • Department of Nephrology, University Hospital of Bordeaux Bordeaux, France
  • AUB Santé foundation, Brest Brest, France
  • Department of Nephrology, University Hospital of Brest Brest, France
View all 40 locations
View Trial Details
Recruiting

Study of WAL0921 in Patients With Glomerular Kidney Diseases

NCT06466135

Conditions
Autoimmune Diseases, Diabetes Complications, Diabetes Mellitus, +18 more
Locations
  • Academic Medical Research Institute Los Angeles, California, United States
  • Colorado Kidney and Vascular Care Denver, Colorado, United States
  • D & H Tamarac Research Center Tamarac, Florida, United States
  • Fides Clinical Research Atlanta, Georgia, United States
View all 50 locations
View Trial Details
Recruiting

Post-Market Study to Assess iTind Safety in Comparison to UroLift

NCT04757116

Conditions
Benign Prostatic Hyperplasia (BPH), Genital Diseases, Genital Diseases, Male, +4 more
Locations
  • Mayo Clinic Arizona Phoenix, Arizona, United States
  • Arizona Urology Specialists Tucson, Arizona, United States
  • Urology Associates of Central California Fresno, California, United States
  • Golden State Urology Sacramento, California, United States
View all 19 locations
View Trial Details
Recruiting

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

NCT06270706

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced or Metastatic Solid Tumor, +64 more
Locations
  • Yale University New Haven, Connecticut, United States
  • Winship Cancer Institute of Emory University Atlanta, Georgia, United States
  • South Texas Accelerated Research Therapeutics (START) Grand Rapids, Michigan, United States
  • NEXT Austin Austin, Texas, United States
View Trial Details
Recruiting

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

NCT07300241

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +23 more
Locations
  • NEO-811 Los Angeles Site Duarte, California, United States
  • NEO-811 San Diego Site San Diego, California, United States
  • NEO-811 Connecticut Site New Haven, Connecticut, United States
  • NEO-811 Chicago Site Zion, Illinois, United States
View Trial Details
Recruiting

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

NCT05433142

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +28 more
Locations
  • Xencor Investigative Site Phoenix, Arizona, United States
  • Xencor Investigative Site Duarte, California, United States
  • Xencor Investigative Site Sacramento, California, United States
  • Xencor Investigative Site New Haven, Connecticut, United States
View all 26 locations
View Trial Details
Recruiting

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

NCT06239272

Conditions
Adipocytic Neoplasm, Angiomatoid Fibrous Histiocytoma, Angiosarcoma, +82 more
Locations
  • Children's Healthcare of Atlanta Atlanta, Georgia, United States
  • Lurie Children's Hospital of Chicago Chicago, Illinois, United States
  • Our Lady of the Lake Children's Hospital Baton Rouge, Louisiana, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details

Related conditions